Last reviewed · How we verify
NCT03092739
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
trial testing PD-L1 Immunocytochemistry (ICC) in Carcinoma, Non-Small-Cell Lung in 184 participants. Completed in 6 June 2018.
8 January 2018
Quick facts
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 184 |
| Start date | 3 May 2017 |
| Primary completion | 8 January 2018 |
| Estimated completion | 6 June 2018 |
| Sites | 8 locations across United Kingdom, Germany, Poland, Switzerland, Spain, Czechia |
Drugs / interventions tested
- PD-L1 Immunocytochemistry (ICC)
- PD-L1 Immunohistochemistry (IHC)
Conditions studied
- Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
- Carcinoma, Small Cell — all drugs for Carcinoma, Small Cell →
Sponsor
Hoffmann-La Roche — full company profile →
Who can join
Eligibility, any sex, with Carcinoma, Non-Small-Cell Lung or Carcinoma, Small Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
PD-L1 expression testing in non-small cell lung cancer.
Teixidó C, Vilariño N, Reyes R, Reguart N. · · 2018 · cited 115× · PMID 29662547 · DOI 10.1177/1758835918763493 -
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L, Conde E, Cappuzzo F, Langfort R, et al · · 2020 · cited 15× · PMID 32721105 · DOI 10.1002/cncy.22324
Verify or expand the search:
- PubMed search for NCT03092739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carcinoma, Non-Small-Cell Lung
Currently open trials in the same condition.
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
- NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
- NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
- NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
- NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
- NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03092739 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
- Last refreshed: 23 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092739.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing